Author: Li, Jue ; Zheng, Xiaoling ; Xu, Xingyu ; Gao, Wenwen ; Wang, Zhengnan ; Liu, Huijun ; Wang, Zhijian ; Wang, Lei ; Chen, Xiaofeng ; Ge, Wangqin ; Wang, Tingzhang ; Wang, Yinhuan ; Mao, Lingfeng

Bifidobacterium is a common bacterium colonizing human intestines which is frequently used to produce probiotic-related products. Since the rapid development of probiotic products field over recent years, improving probiotic-related testing methods, as well as conducting systematic safety evaluations is urgently needed. Advances in sequencing technology enable clinicians to access the complete genome of bacteria more effectively via whole genome sequencing, thereby providing a solution for the safety evaluation of probiotics. In our current study, seven samples of the Bifidobacterium spp. were isolated from probiotic products, and genomic analysis were used to improve the identification of Bifidobacterium spp. at the species and subspecies levels. Notably, the obtained high-quality complete genomes were employed to predict the genetically encoded drug resistance and virulence attributes of seven Bifidobacterium strains, which further improve the evaluation of probiotics safety. Genes imparting beneficial functional properties, as well as those associated with colonization and survival within the gastrointestinal tract were presented in all strains. In addition, whole genome sequencing-based analysis combined with phylogenetic trees could help identify the subspecies and facilitate the analysis of the existing homology of samples and the previously reported differences between strains. Our study evaluated the accuracy of mainstream approaches in identifying the bacteria probiotic-related products, and uncovered the deceptive facts in bacteria labeling. Our findings could provide the experimental basis for subspecies level bacterial identification in probiotic-related industry, and to help establish a standard systematic safety evaluation method.

100 Deals associated with Hangzhou Baiyi Technology Co., Ltd.

100 Translational Medicine associated with Hangzhou Baiyi Technology Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 19 Jan 2026

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hangzhou Baiyi Technology Co., Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 19 Jan 2026

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing